Cannabis Health Risks: Peer-Reviewed Research Consensus
Overview
The research base for cannabis health risks includes 84 peer-reviewed studies spanning 2025–2026. Of these, 7 provide strong evidence, including 4 meta-analyses and 0 randomized controlled trials. Key findings with strong support include: meta-analysis of 13 studies found prenatal cannabis exposure significantly increased odds of small-for-gestational-age and low birth weight outcomes, and study of 289,000 surgical patients found cannabis use disorder increased post-surgical cardiovascular risk by 26%, with recreational use risky only for those with high baseline cardiac risk. However, several findings remain debated, and the evidence is not uniform across all areas. Many studies have methodological limitations including small sample sizes, short follow-up periods, and reliance on self-reported data.
What the Research Shows
Findings supported by multiple peer-reviewed studies. Stronger evidence means more consistency across study types.
Meta-analysis of 13 studies found prenatal cannabis exposure significantly increased odds of small-for-gestational-age and low birth weight outcomes
Strong EvidenceStudy of 289,000 surgical patients found cannabis use disorder increased post-surgical cardiovascular risk by 26%, with recreational use risky only for those with high baseline cardiac risk
Moderate EvidenceWhere Scientists Disagree
Areas where research shows conflicting results or ongoing scientific debate.
NHANES analysis of 3,690 adults found marijuana/hashish use associated with 4
Moderate EvidenceConnecticut crash-toxicology data linkage found alcohol, cannabis, and other drugs significantly predicted driver injury, with lack of safety equipment as the strongest predictor
Moderate EvidenceLarge cohort study of 363,952 births found prenatal cannabis use associated with a rare abdominal wall defect (omphalocele) but not with 36 other major birth defects
Moderate EvidenceRemoving cannabis as a urine drug screening indication in a maternity unit eliminated racial disparities in testing and CPS reporting without missing other substance use
Moderate EvidenceWhat We Still Don't Know
- Only 0 randomized controlled trials exist out of 84 studies — most evidence is observational or from reviews.
- Long-term prospective studies tracking outcomes over 5+ years are largely absent from the literature.
- Research on diverse populations (different ages, ethnicities, and medical backgrounds) remains limited.
Evidence Breakdown
Distribution of study types in this research area. Higher-tier evidence (meta-analyses, RCTs) provides stronger conclusions.
Key Studies
The most impactful research in this area.
Meta-Analysis Links Prenatal Cannabis to Smaller Babies
This meta-analysis pools evidence from multiple studies to provide a clearer picture of prenatal cannabis risks. The significant findings for birth size outcomes add confidence to what individual studies have suggested.
Meta-analysis found cannabis use associated with 53% higher all-cause mortality, but evidence quality was low
This is the first meta-analysis to synthesize evidence on cannabis use and all-cause mortality. The finding of a 53% increased risk is notable but comes with substantial caveats: high heterogeneity, potential confounding, and the association disappearing in patient populations suggest the relationsh
Cannabis Users Had 48% Higher Risk of Cardiovascular Events in Large Meta-Analysis
Whether cannabis causes cardiovascular disease has been debated for years. This meta-analysis of nearly 1.9 million people provides the strongest pooled estimate to date, showing a significant association with composite cardiovascular events even if individual endpoints fall short of significance.
Cannabis Use Linked to 29% Higher Heart Attack Risk and Double the Cardiovascular Death Risk
This is one of the most comprehensive quantitative assessments of cannabis cardiovascular risk. The elevated cardiovascular death risk (2.1x) is particularly concerning given increasing cannabis use and the often-overlooked cardiac effects.
CBD and THC Can Interfere With How Your Body Processes Other Medications
With millions of people using CBD products alongside prescription medications, understanding drug interactions is critical for safety. The strong inhibition of CYP3A4 alone is clinically significant — this enzyme metabolizes drugs like blood thinners, statins, and anti-seizure medications.
Cannabis use disorder increased post-surgical cardiovascular risk by 26% in a study of 289,000 patients
This is one of the largest studies linking cannabis use to post-surgical cardiovascular complications. The critical finding that risk depends on both the type of cannabis use (disorder vs recreational) and baseline cardiac risk provides actionable information for surgical risk assessment.
Research Timeline
How our understanding of this topic has evolved.
2020–present
84 studies published. Includes 4 meta-analyses, 7 strong-evidence studies.
About This Consensus
This consensus synthesizes 84 peer-reviewed studies: 4 meta-analyses (5%), 33 observational studies (39%), 9 reviews (11%), 9 case studies (11%), 29 other study types (35%). Studies span from the earliest available research through 2025. Evidence strength ratings reflect study design, sample size, and replication across multiple research groups.
This page synthesizes findings from 84 peer-reviewed studies. It is not medical advice. Always consult a healthcare provider for personal health decisions.